Cannabis could help alleviate depression and suicidality among people with PTSD

Cannabis may be helping Canadians cope with the effects of post-traumatic stress disorder (PTSD), new research suggests. In an analysis of health survey data collected by Statistics Canada from more than 24,000 Canadians, researchers from the BC Centre on Substance Use (BCCSU) and University of British Columbia (UBC) found that people who have PTSD but do not medicate with cannabis are far more likely to suffer from severe depression and have suicidal thoughts than those who reported cannabis use over the past year.

The study, published today in the Journal of Psychopharmacology, is the first to document the relationships between PTSD, cannabis use, and severe mental health outcomes in a sample representative of the population.

"We know that with limited treatment options for PTSD, many patients have taken to medicating with cannabis to alleviate their symptoms," says lead author Stephanie Lake, a research assistant at the BCCSU and PhD candidate at UBC's school of population and public health. "However, this is the first time that results from a nationally representative survey have shown the potential benefits of treating the disorder with cannabis."

Data was obtained from Statistics Canada's 2012 Canadian Community Health Survey - Mental Health (CCHS-MH), which covers Canadians aged 15 and older. Among 24,089 eligible respondents, 420 reported a current clinical diagnosis of PTSD. In total, 106 people with PTSD, or 28.2 per cent, reported past-year cannabis use, compared to 11.2 per cent of those without PTSD.

The researchers found that PTSD was significantly associated with a recent major depressive episode and suicidal ideation among people who don't use cannabis. Specifically, cannabis non-users with PTSD were about seven times more likely to have experienced a recent major depressive episode and 4.7 times more likely to have thoughts of suicide compared to cannabis non-users without PTSD, the researchers found.

Among cannabis-using respondents, PTSD was not associated with a recent depressive episode or suicide ideation. Over one-quarter of Canadians with PTSD reported past-year cannabis use, which is remarkably high compared to the prevalence of recent use in the general Canadian population (estimated at 11.4 per cent in the present study).

People exposed to trauma, including survivors of acute injury, conflict, violence and disaster, suffer from depression, suicide, and substance use disorders at disproportionately high rates compared to the general population. Canada is estimated to have one of the highest prevalence rates of PTSD worldwide, affecting an estimated 9.2 per cent of the population.

"We're only just beginning to understand what the therapeutic potential of cannabis may be for a variety of health conditions," says senior author Dr. M-J Milloy, research scientist at BCCSU and Canopy Growth Professor of Cannabis Science at UBC. "These findings are promising, and merit further study in order to fully understand the benefits of cannabis for people living with PTSD."

Stephanie Lake, Thomas Kerr, Jane Buxton,  Zach Walsh, Brandon Marshall, Evan Wood, M-J Milloy.
Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? Evidence from a population-based cross-sectional study of Canadians.
Journal of Psychopharmacology, November 5, 2019. doi: 10.1177/0269881119882806.

Most Popular Now

BioMotiv and Bristol-Myers Squibb announce the lau…

BioMotiv, a mission-driven drug development accelerator associated with The Harrington Project for discovery and development, that advances breakthrough discoveries from ...

CEPI and GSK announce collaboration to strengthen …

CEPI, the Coalition for Epidemic Preparedness Innovations, and GSK announced a new collaboration aimed at helping the global effort to develop a vaccine for the 2019-nCoV...

Sandoz completes acquisition of Aspen's Japanese o…

Sandoz today announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen ...

Roche reports very strong results in 2019

In 2019, Group sales rose 9% to CHF 61.5 billion and core EPS grew 13%, ahead of sales. The core operating profit increased 11%, reflecting the strong underlying business...

Sanofi brain-penetrant BTK inhibitor meets primary…

The Sanofi Phase 2b study evaluating its investigational BTK (Bruton's tyrosine kinase) inhibitor (SAR442168), an oral, brain-penetrant, selective small molecule, achieve...

Sanofi completes acquisition of Synthorx, Inc.

Sanofi announced the successful completion of its acquisition of Synthorx, Inc. ("Synthorx") for $68 per share in cash. "The acquisition of Synthorx perfectly aligns w...

Merck donates one billionth praziquantel tablet

Merck, a leading science and technology company, today announced that it has already donated 1 billion tablets of praziquantel, the standard medication for the treatment ...

WHO, China leaders discuss next steps in battle ag…

The Director-General of the World Health Organization (WHO), Dr Tedros Adhanom Ghebreyesus, met President Xi Jinping of the People's Republic of China in Beijing. They sh...

Poliovirus therapy shows potential as cancer vacci…

A modified form of poliovirus, pioneered at Duke Cancer Institute as a therapy for glioblastoma brain tumors, appears in laboratory studies to also have applicability for...

AstraZeneca divests rights to established hyperten…

AstraZeneca has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Ze...

Botanical drug is shown to help patients with head…

In a UCLA-led phase I clinical trial, a new plant-based drug called APG-157 showed signs of helping patients fight oral and oropharyngeal cancers. These cancers are locat...

FDA approves first drug for treatment of peanut al…

Today the U.S. Food and Drug Administration approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp] to mitigate allergic reactions, including anaphylaxis, tha...